Mouli Pal
Overview
Explore the profile of Mouli Pal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Su S, Shayo S, Bao W, Pal M, Dou K, et al.
J Clin Invest
. 2023 Jul;
133(18).
PMID: 37490346
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by painful vaso-occlusive crises (VOC) and chronic hemolysis. The mononuclear phagocyte system is pivotal to SCD pathophysiology, but the mechanisms governing...
2.
Wang R, Bao W, Pal M, Liu Y, Yazdanbakhsh K, Zhong H
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35091454
Background: Circulating monocytes are functionally heterogeneous and can be divided into classical (CMo), intermediate (IMo), and non-CMo/patrolling monocyte (PMo) subsets. CMo can differentiate into PMo through IMo. PMos have been...
3.
Liu Y, Pal M, Bao W, Shi P, Lobo C, An X, et al.
Blood
. 2021 Jun;
138(13):1162-1171.
PMID: 34166491
Patients with sickle cell disease (SCD) suffer from intravascular hemolysis-associated vascular injury and tissue damage. Classical monocytes (CMo), which are the most abundant of circulating monocytes, are activated in SCD,...
4.
Pal M, Bao W, Wang R, Liu Y, An X, Mitchell W, et al.
Blood
. 2020 Nov;
137(2):269-280.
PMID: 33152749
Red blood cell alloimmunization remains a barrier for safe and effective transfusions in sickle cell disease (SCD), but the associated risk factors remain largely unknown. Intravascular hemolysis, a hallmark of...
5.
Luchsinger L, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, et al.
J Clin Microbiol
. 2020 Sep;
58(12).
PMID: 32917729
The development of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following infection or vaccination is likely to be critical for the development of sufficient population immunity...
6.
Luchsinger L, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, et al.
medRxiv
. 2020 Jun;
PMID: 32577675
The development of neutralizing antibodies (nAb) against SARS-CoV-2, following infection or vaccination, is likely to be critical for the development of sufficient population immunity to drive cessation of the COVID19...